Understanding the power of CAR T cells in revolutionizing cancer treatment

Logo

Understanding the power of CAR T cells in revolutionizing cancer treatment

Cancer treatment has evolved significantly over the years, but one of the most promising and groundbreaking advancements is the use of CAR T cells. Short for Chimeric Antigen Receptor T cells, this form of immunotherapy has captured the medical world's attention for its potential to combat some of the most difficult-to-treat cancers.

In this blog post, we’ll explore what CAR T cells are, how they work, and the potential they hold for the future of cancer therapy.

Read time: 5–10 minutes

This information is intended for biological researchers and should not be viewed as advice on the use of CAR T cells in the treatment of cancer.

Check out our blog and get up to speed on CAR T–cell therapies reshaping modern oncology

Content overview

Content

  • How does CAR T–cell therapy work?
  • Types of CAR T cells by generation: How has CAR design evolved?
  • CAR T–cell therapy successes
  • What are the challenges and side effects of CAR T–cell therapies?
  • What new developments are there in CAR T–cell therapies and research?

How does CAR T–cell therapy work?

CAR T–cell therapy is a form of immunotherapy where a patient’s T cells are genetically engineered to express a CAR, allowing them to recognize and attack cancer cells. These modified T cells are expanded in the lab and reinfused into the patient, where they specifically target cancer-associated antigens, such as CD19 in B cell cancers. Here's how it works step by step:1

  • Genetic engineering: In a laboratory, the T cells are altered to express the CAR on their surface. This engineered receptor is tailored to recognize specific proteins on the surface of cancer cells.
  • Multiplication: After the T cells are modified, they are grown in large quantities, to ensure an effective attack on the cancer.
  • Infusion: The engineered CAR T cells are infused back into the patient. This part of the process typically follows a short course of chemotherapy to reduce the number of existing immune cells, allowing the new CAR T cells to function more efficiently.
  • Cancer attack: Once inside the body, the CAR T cells seek out and bind to the cancer cells, triggering their destruction.

Icon showing a shining lightbulb with an exclamaiton mark on it

Did you know?

To enhance safety, some CAR T cell products include "suicide genes" that can be activated to eliminate CAR T cells in case of severe side effects or adverse reactions, providing a fail-safe mechanism. Some examples of suicide genes include inducible caspase 9 (iCasp9, CAR elimination through activation of the downstream caspase molecules), herpes simplex virus thymidine kinase (HSV-TK, CAR elimination through formation of toxic GCV-triphosphates), CD20/EGFR markers (CAR elimination through antibodies rituximab or cetuximab), and FKBP-caspase fusion proteins (CAR elimination through activation of the downstream caspase molecules).2

Types of CAR T cells by generation: How has CAR design evolved?

CAR T cells are categorized based on several factors, such as the generation of the CAR design (from first to fifth generation). CAR T–cell therapy has evolved through multiple generations of CAR design, improving their function, persistence, and effectiveness in fighting cancer.3 Here’s how the generations differ:

Overview of the primary types of CAR T cells

 First-generation CAR T cellsSecond-generation CAR T cellsThird-generation CAR T cellsFourth-generation CAR T cellsFifth-generation CAR T cells
StructureIntracellular signaling domain CD3ζ.Intracellular signaling domain CD3ζ .

One co-stimulatory domain (e.g., CD28 or 4-1BB).
Intracellular signaling domain CD3ζ .

Two or more co-stimulatory domains (e.g., CD28 or 4-1BB).
Intracellular signaling domain CD3ζ .

Co-stimulatory domains (like CD28 or 4-1BB).

NFAT-responsive cassette containing cytokines (e.g., IL-12 or IL-2).

Also known as T cells Redirected for Universal Cytokine Killing (TRUCKs) or armored CAR T cells.
Intracellular signaling domain CD3ζ.

Co-stimulatory domains (e.g., CD28 or 4-1BB).

Cytokine receptor domain (e.g., IL-2Rβ and STAT3).
Mode of action and characteristicsOften less effective due to poor proliferation, persistence, and lacking co-stimulatory signals, resulting in reduced survival and limited anti-tumor efficacy.Adding a co-stimulatory domain boosts T cell activation, persistence, and cytokine production, showing success, especially in blood cancers.Co-stimulatory signals enhance CAR T cell potency, improving proliferation, activation, and survival over earlier generations.These CAR T cells reshape the tumor microenvironment by releasing cytokines to recruit and activate immune cells, boosting anti-tumor response. Being explored for solid tumors, which are harder to treat.Designed to activate transcription factors for T cell proliferation and persistence, countering immunosuppressive tumors.
Available therapies or development statusNot widely used and currently considered obsolete.Most successful generation, with multiple FDA-approved therapies for B cell cancers, not limited to but including: Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene Ciloleucel). For a full overview, see table below.Ongoing clinical trials, but not yet FDA-approved.Early-phase clinical trials, with promising but limited human data.Mostly in preclinical development and early-phase trials.

CAR T–cell therapy successes

CAR T–cell therapy has shown remarkable success in treating certain types of blood cancers, particularly in patients who have not responded to conventional treatments like chemotherapy and radiation. Several FDA-approved CAR T–cell therapies have revolutionized the treatment of B cell malignancies and multiple myeloma, showing high response rates and durable remissions.4

Overview of CAR T–cell therapies approved by the FDA as of Q2 2025.

IndicationTargetTreatmentFDA status
Acute Lymphoblastic Leukemia (ALL)CD19Kymriah (Tisagenlecleucel)FDA approved (2017)5
Relapsed or refractory (r/r) diffuse large B cell lymphoma (DLBCL)FDA approved (2018)6
R/r follicular lymphoma (FL)FDA approved (2022)7
R/r DLBCLCD19Yescarta (Axicabtagene Ciloleucel)FDA approved (2017)8
R/r follicular lymphoma (FL)FDA approved (2021)9
R/r (r/r) Mantle cell lymphoma (MCL)CD19Tecartus (Brexucabtagene Autoleucel)FDA approved (2020)10
R/r B cell precursor ALLFDA approved (2021)11
R/r large B cell lymphoma (LBCL)CD19Breyanzi (Lisocabtagene Maraleucel)FDA approved (2021)12
R/r CLL or SLLFDA approved (2024)13
R/r FLFDA approved (2024)14
R/r MCLFDA approved (2024)15
R/r multiple myeloma (MM)BCMAAbecma (Idecabtagene Vicleucel)FDA approved (2021)16
R/r MMBCMACarvykti (Ciltacabtagene Autoleucel)FDA approved (2022)17

What are the challenges and side effects of CAR T–cell therapies?

Despite the promise of CAR T–cell therapy, it is not without its challenges.18 These challenges include:

  • Cytokine Release Syndrome (CRS): A significant side effect is CRS, where the immune system overreacts to activated CAR T cells, causing symptoms ranging from mild (fever, fatigue) to severe (low blood pressure, organ dysfunction).
  • Neurological toxicities: These include confusion, seizures, or difficulty speaking. Although the side effects are usually temporary, they can be severe.
  • Tonic signaling: Tonic signaling refers to the phenomenon where CAR T cells are persistently activated even in the absence of their target antigen. This can lead to T cell exhaustion, a state in which T cells lose their functionality over time. Modifications in CAR design, especially in the co-stimulatory domains (e.g., CD28, 4-1BB), are aimed at reducing tonic signaling to prolong CAR T–cell effectiveness and prevent exhaustion.
  • Relapse: Although CAR T–cell therapy has been successful for many, some patients may relapse after treatment, either because the cancer develops resistance to the CAR T cells or because not all cancerous cells were targeted effectively.

Person operating a CliniMACS Prodigy with a document icon
Research highlight

Read more about how the CliniMACS Prodigy® System, CD19 CAR vector, REAfinity® Antibodies, and MACSQuant® Flow Cytometer contributed to producing CAR T cells for the treatment of NHL.

Automated manufacture of autologous CD19 CAR-T cells for treatment of non-hodgkin lymphoma
Jackson, Z. et al. (2020) Front Immunol. 11:1941. | Read article

Icon showing publications
Research highlight

Read more about how the CliniMACS Prodigy System, REAfinity Antibodies, and MACSQuant Flow Cytometer contributed to producing dual targeting of CD19 and CD22 CAR T cells.

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Spiegel, JY. et al. (2021) Nat Med. 27(8):1419-1431. | Read article

What new developments are there in CAR T–cell therapies and research?

CAR T–cell therapy is a groundbreaking cancer treatment that reprograms the immune system to target tumors. Though challenges remain, ongoing advances in research and genetic engineering are paving the way for broader applications in oncology. The future of CAR T–cell therapy is bright, with ongoing research aiming to improve its efficacy and broaden its application to more cancer types.19 Some exciting developments include:

  • Dual-targeting CAR T cells: As the name indicates, these CARs are designed to target two cancer antigens simultaneously. This is done to overcome cancer’s ability to evade the immune response by downregulating a single antigen. For example, some CAR T cells target both CD19 and CD22 in leukemia, aiming to reduce relapse rates that occur when cancer cells lose CD19 expression.20
  • SynNotch CAR T cells: Some CAR T cells are being designed using synthetic notch (SynNotch) receptors, allowing them to respond to complex Boolean logic inputs. For example, they may only activate if two antigens are simultaneously present ("AND" gate), or activate if one antigen is present but inhibited if another antigen is also present ("NOT" gate). This makes them more precise in targeting, reducing off-tumor effects, and enhancing safety.21
  • Allogeneic (universal) CAR T cells: One area of innovation is in developing "off-the-shelf" CAR T cells from healthy donors, rather than engineering each patient’s own cells. This could make the treatment faster and more affordable. However, a major challenge remains the risk of graft-versus-host disease.22

Advances in solid tumor targeting

Researchers are developing CAR T–cell therapies targeting specialized proteins in solid tumors, such as malignant glioblastoma, non-small cell lung cancer, pancreatic carcinoma, adenocarcinomas, and many others. Studies have shown that combining CAR T–cell therapy with targeted agents can effectively delay the emergence of drug-resistant cells, offering new hope for solid cancer patients.

The current landscape of CAR T–cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.
Daei Sorkhabi, A. et al. (2023) Front Immunol. 14:1113882. | Read article

Addressing secondary cancer risks

Studies are investigating the long-term risks associated with CAR T–cell therapy, including the potential development of secondary cancers. Research has identified genetic changes in T cell lymphoma cells that may be linked to CAR T–cell therapy, highlighting the need for ongoing monitoring and risk assessment.

Risk of second tumors and T cell lymphoma after CAR T–cell therapy.
Hamilton, MP. et al. (1014) N Engl J Med. 390(22):2047-2060. | Read article

CAR T–cell therapy represents a revolutionary approach in the fight against cancer. By harnessing the body’s own immune system and reprogramming it to target cancer cells, this therapy offers hope for patients who previously had few options left. While challenges remain, ongoing research and advancements in genetic engineering hold the potential to expand the reach of CAR T cells, making them a key player in the future of oncology.

You have previously chosen International as your location.
What do you want to do?